Gantenerumab 

Gantenerumab is a fully humanized anti-Aβ IgG1 monoclonal antibody. Gantenerumab can specifically bind to Aβ fibrils and plaques and can be used in Alzheimer's disease research^[1].

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Human

Gantenerumab (0.07-7 nM; 40-72 h) can reduce the Aβ plaque load in a concentration-dependent manner in the co-culture system of brain tissue sections from AD patients and primary human macrophages or microglia, and with an EC₅₀ of approximately 0.7 nM^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Gantenerumab (20 mg/kg; intravenous injection; once a week; 5 months) has a protective effect in PS2APP transgenic mice and can reduce the number of Aβ amyloid plaques^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

146280.00

1043556-46-2

Liquid

Colorless to light yellow

[Gantenerumab]

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 kappa

• 
  Loaded Gantenerumab on AHC2 biosensor, can bind Amyloid Precursor/Beta-APP42 Protein, Human (His-GST, HY-P76168) with an affinity constant of 5.257E-11 M as determined in BLI assay.

• [1]. Bernd Bohrmann, et al. Gantenerumab: a novel human anti-Aβ antibody demonstrates sustained cerebral amyloid-β binding and elicits cell-mediated removal of human amyloid-β. J Alzheimers Dis. 2012;28(1):49-69.  [Content Brief]